Amgen shares plunged after a rival's Phase 3 failure that referenced Amgen’s similar olpasiran and prompted a downgrade.
Amgen shares plunged after a rival drug failed a pivotal Phase 3 trial and analysts cut the stock. The news directly referenced Amgen’s similar Lp(a) candidate olpasiran and spurred a downgrade. That combination pressured Amgen's share price sharply.
Novartis disclosed that pelacarsen failed a pivotal Phase 3 cardiovascular outcomes trial, which is a setback for that program.
Stryker shares fell along with other medtech names as investors sold names tied to the sector after the clinical read-through.
Roivant jumped after its subsidiary reported success in a mid-stage trial for mosliciguat, lifting the stock sharply.
Bloom Energy rallied on confirmation it will join the S&P 500 and on an analyst price-target lift.
Intel rose after reports of planned price increases, an analyst upgrade, and progress on advanced wafer processing.
Follow Amgen Inc. (AMGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AMGN